Research ArticleINFECTIOUS DISEASE

Plasmodium products persist in the bone marrow and promote chronic bone loss

See allHide authors and affiliations

Science Immunology  02 Jun 2017:
Vol. 2, Issue 12, eaam8093
DOI: 10.1126/sciimmunol.aam8093

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Plasmodium leftovers cause bone loss

Individuals who recover from malarial infection may develop long-term consequences, such as bone loss and growth retardation. Lee et al. now report that Plasmodium by-products retained in the bone marrow lead directly to bone loss. Infection with a mutant Plasmodium that lacked the by-product hemozoin did not induce bone loss. Mechanistically, these products induced MyD88-dependent inflammatory responses in osteoclast and osteoblast precursors, resulting in bone resorption. Treating infected animals with alfacalcidol, a vitamin D3 analog, could prevent this bone loss, suggesting that combining bone therapies with antimalarial drugs may prevent bone loss in infected individuals.